Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Windward Bio Group AG

WWBNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 16, 2026Accepted Nov 16, 2026, 6:00 PM ESTFiling CIK 2145089Accession 0001618945-26-000007
Share

Structured filing — 4

form4-11162026_061101.xml

Open full document ↗

Filing details

Report period
2026-11-12
Issuer
WINDWARD BIO GROUP AG
Issuer CIK
0002145089
Trading symbol
WWB

Reporting owner 1

Name
Applebaum Scott
Reporting owner CIK
0001618945
Relationship
Officer
Officer title
Chief Legal & Corp Dev Officer
Address
C/O WINDWARD BIO GROUP AG, AESCHENPLATZ 6, BASEL, SWITZERLAND, V8, 4052

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Shares2026-11-16A · Form 433,206[F1]A0960,966D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Employee Share Option (Right to Buy)172026-11-12A · Form 4180,160A0[F2]2036-11-12Common Shares180,160180,160D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
Represents a restricted share unit ("RSU") award. One quarter (1/4th) of the RSU will vest on May 11, 2027, and the remainder will vest in eight substantially equal installments on each subsequent May 20, August 20, November 20 and February 20, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.↩ 1
F2
This option will vest in 36 substantially equal monthly installments on the last day of the relevant month commencing on December 31, 2026, subject to the Reporting Person's continuous service as of each such vesting date.↩ 1

Signature 1

Signed
/s/ Scott Applebaum
Date
2026-11-16

Company context

We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. We estimate these diseases collectively represent a $60 billion peak market opportunity for biologic therapies, as we believe the majority of patients eligible to receive biologic treatment for these diseases remain untreated. Our product candidates can potentially address this significant unmet need, allow for treatment of a broader population of patients, improve efficacy, and improve dosing convenience and adherence to treatment. We estimate that these diseases collectively affect more than 100 million people in the United States, EU5 (France, Germany, Italy, Spain, and the United Kingdom), and Japan and more than 8 million are eligible for biologics treatment.

Current securities

Recent company filings

  1. 4 filingNov 18, 2026
  2. 4 filingNov 18, 2026
  3. 4 filingNov 18, 2026
  4. 4 filingNov 16, 2026
  5. 4 filingNov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.